Literature DB >> 264052

Elective induction of labor conducted under lumbar epidural block. I. Labor induction by amniotomy and intravenous oxytocin.

S Vroman, A Yo Le Sian, M Thiery, D de Hemptinne, K Vanderheyden, H Van Kets, G Martens, R Derom, G Rolly.   

Abstract

Epidural analgesia (bupivacaine) was administered during labor after amniotomy, in some cases supplemented by intravenous oxytocin. A higher incidence of transient uterine hypertonus was seen after blocking. Fetal heart rate changes mainly took the form of bradycardia (in association with uterine hypertonus). At birth, the maternal biochemical condition was characterized by a lower degree of metabolic acidosis, compared to normal unanesthetized controls. The fetuses displayed a slight degree of hypoxia and hypercapnia. The mechanisms underlying these modifications are discussed. Epidural blockade in combination with elective induction of labor, whether or not supplemented by intravenous oxytocin, may carry a risk. Its magnitude is considered acceptable for both mother and fetus provided they are constantly under close surveillance, limited amounts of bupivacaine are administered and the second stage of labor is kept short. However, some warnings against epidural analgesia apply to patients with placental insufficiency and very active labor.

Entities:  

Keywords:  Analgesia--side effects; Biology; Cardiovascular Effects; Clinical Research; Embryo; Endocrine System; Fetus; Genitalia; Genitalia, Female; Hormones; Oxytocin; Physiology; Pituitary Hormones; Pregnancy; Puerperium; Reproduction; Research Methodology; Treatment; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1977        PMID: 264052     DOI: 10.1016/0028-2243(77)90025-9

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

1.  Continuous lumbar epidural analgesia for labour and delivery.

Authors:  R Derom; M Thiery; G Rolly
Journal:  Br Med J       Date:  1979-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.